206 related articles for article (PubMed ID: 12688312)
21. Targeting PRAME for acute myeloid leukemia therapy.
Yang J; Chen M; Ye J; Ma H
Front Immunol; 2024; 15():1378277. PubMed ID: 38596687
[TBL] [Abstract][Full Text] [Related]
22. PRAME gene expression in childhood acute lymphoblastic leukemia.
Steinbach D; Viehmann S; Zintl F; Gruhn B
Cancer Genet Cytogenet; 2002 Oct; 138(1):89-91. PubMed ID: 12419593
[TBL] [Abstract][Full Text] [Related]
23. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
24. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Hasegawa H; Yasukawa M
Cancer Sci; 2008 Jul; 99(7):1414-9. PubMed ID: 18422754
[TBL] [Abstract][Full Text] [Related]
25. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
26. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia.
Tajeddine N; Millard I; Gailly P; Gala JL
Clin Chem Lab Med; 2006; 44(5):548-55. PubMed ID: 16681423
[TBL] [Abstract][Full Text] [Related]
27. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
28. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.
Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K
Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770
[TBL] [Abstract][Full Text] [Related]
29. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
[TBL] [Abstract][Full Text] [Related]
30. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
31. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
32. The expression of PRAME in chronic lymphoproliferative disorders.
Proto-Siqueira R; Falcão RP; de Souza CA; Ismael SJ; Zago MA
Leuk Res; 2003 May; 27(5):393-6. PubMed ID: 12620290
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
34. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
35. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
36. PRAME Gene Expression in Acute Leukemia and Its Clinical Significance.
Ding K; Wang XM; Fu R; Ruan EB; Liu H; Shao ZH
Cancer Biol Med; 2012 Mar; 9(1):73-6. PubMed ID: 23691459
[TBL] [Abstract][Full Text] [Related]
37. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.
Morandi F; Chiesa S; Bocca P; Millo E; Salis A; Solari M; Pistoia V; Prigione I
Neoplasia; 2006 Oct; 8(10):833-42. PubMed ID: 17032500
[TBL] [Abstract][Full Text] [Related]
38. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.
Abdelmalak CA; Yahya RS; Elghannam DM; El-Khadragy AE; Abd El Messih HM
Clin Lab; 2014; 60(1):55-61. PubMed ID: 24600975
[TBL] [Abstract][Full Text] [Related]
39. PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling.
Xu Y; Rong LJ; Meng SL; Hou FL; Zhang JH; Pan G
Eur Rev Med Pharmacol Sci; 2016; 20(6):1057-63. PubMed ID: 27049257
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.
Steinbach D; Hermann J; Viehmann S; Zintl F; Gruhn B
Cancer Genet Cytogenet; 2002 Mar; 133(2):118-23. PubMed ID: 11943337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
